Drug-related Deaths 2025-11-05

Opened the debate

I extend my thanks to Mr Speaker for providing the opportunity to discuss the crucial matter of drug-related deaths. I declare an interest as the unremunerated chair of the Centre for Evidence Based Drug Policy, a think-tank in this policy space. The Office for National Statistics reported last month that deaths related to drug poisonings have increased for the 12th consecutive year, and have consequently reached an all-time high once again. In 2024, there were 5,565 deaths related to drug poisoning in England and Wales, with just under half of those confirmed to involve an opiate. I stress that every single one of those lives mattered, and every single one of those deaths was preventable. I am afraid to say that limited progress has been made since a similar debate was held eight months ago. There are huge regional disparities in drug deaths across the country, with Stoke-on-Trent having the highest number of drug-related deaths involving synthetic cathinones, known as monkey dust. The issue is not specific to my constituency; it affects every part of the UK. I welcome the recent changes to human medicines regulation that further expanded access to naloxone but argue for naloxone to be available rapidly and reliably in every community pharmacy in the UK. I also emphasise the need for opt-out pathways for naloxone distribution, same-day linkage to community treatment, and a clear pathway for handover care for people struggling with substance use disorders. The cost of illegal drug use in England is estimated at £20 billion annually, with 48% attributed to drug-related crime and 33% to harms linked to drug-related deaths and homicide. For every £1 spent on treatment, £4 are saved through reduced demand on the health and justice systems. Long-term funding for organisations delivering services is essential to provide consistent training and scale according to demand.

Government Response

Congratulates Charlotte Nichols for securing the debate and acknowledges the rising drug-related deaths in the UK. Confirms commitment through the health mission to ensure longer, healthier lives and safer streets mission focusing on reducing violence caused by illicit drugs market. Emphasises regular collaboration with counterparts across the four nations of the UK to tackle drug-related issues. Highlights government's work to fund and improve drug treatment and recovery services aiming at reducing social inequalities. We've committed to providing evidence-based, high-quality treatment for individuals with drug problems. In addition to the public health grant, we are offering local authorities an additional £310 million in 2025-26 to enhance drug and alcohol treatment services. There are now nearly 345,000 people receiving structured treatment in England, which is a record high number. Our Department remains vigilant regarding new threats posed by drugs like synthetic opioids, ketamine, and THC vapes, particularly concerning young people. We have launched a public awareness campaign targeting these dangers with online films aimed at 16 to 24-year-olds. Resources are being distributed to local health teams, youth services, schools, universities, and others to address this issue. Enhanced surveillance systems and data collection methods are in place for better real-time understanding of current drug-related harms. Data on factors related to drug deaths is provided to local areas along with a self-assessment toolkit. Care pathways between drug treatment and physical health services are being improved as recommended by Dame Carol Black, focusing on earlier intervention and treating co-occurring conditions. We have made legislative changes allowing more services to supply naloxone without prescription to enhance accessibility. The Government is committed to reducing the harms of illicit drugs through a harm reduction and public health approach.